Free tool
FAERS Monitor: Blincyto
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125557 or its brand name (Blincyto, Blinatumomab). Reports on generic versions are filed under their own applications.
Reports
10,722
Serious
8,619
80% of reports
Hospitalization
2,884
Death reported
1,935
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia1,187
- cytokine release syndrome1,150
- acute lymphocytic leukaemia recurrent1,121
- off label use793
- death674
- neurotoxicity584
- drug ineffective448
- headache379
- neutropenia333
- febrile neutropenia313
- therapy non-responder291
- tremor287
- seizure279
- infection268
- acute lymphocytic leukaemia251
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 8 |
| 2015 | 446 |
| 2016 | 712 |
| 2017 | 808 |
| 2018 | 803 |
| 2019 | 865 |
| 2020 | 789 |
| 2021 | 1,013 |
| 2022 | 959 |
| 2023 | 1,100 |
| 2024 | 1,297 |
| 2025 | 1,065 |
| 2026 | 857 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,437 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute lymphocytic leukaemia recurrentSignal | 1,121 | 1504.9 | 1395.5 | 952,830 |
| acute lymphocytic leukaemiaSignal | 251 | 190.7 | 167.8 | 43,007 |
| cytokine release syndromeSignal | 1,150 | 119.2 | 112.7 | 127,120 |
| neurotoxicitySignal | 584 | 67.6 | 62.4 | 37,010 |
| therapy non-responderSignal | 291 | 12.8 | 11.4 | 3,133 |
| febrile neutropeniaSignal | 313 | 9.3 | 8.3 | 2,305 |
| pyrexiaSignal | 1,187 | 6.7 | 6.4 | 5,884 |
| neutropeniaSignal | 333 | 4.8 | 4.3 | 1,006 |
| seizureSignal | 279 | 4.7 | 4.2 | 824 |
| infectionSignal | 268 | 3.6 | 3.2 | 512 |
| tremorSignal | 287 | 3.4 | 3.0 | 486 |
| off label use | 793 | 1.8 | 1.7 | 280 |
| death | 674 | 1.5 | 1.4 | 130 |
| headache | 379 | 1.2 | 1.1 | 11 |
| drug ineffective | 448 | 0.7 | 0.6 | 79 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.